about
MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies.Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool.Nonreplicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro.GM-CSF gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens.Non-replicating recombinant vaccinia virus expressing CD80 to enhance T-cell stimulation.Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation.Virosomes as new carrier system for cancer vaccines.Enhanced chondrocyte proliferation and mesenchymal stromal cells chondrogenesis in coculture pellets mediate improved cartilage formation.Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients.Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigenHigh expression of MAGE-3 protein in squamous-cell lung carcinomaFLT3 ligand gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimensNY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray studyAdvanced liposomal vectors as cancer vaccines in melanoma immunotherapy
P50
Q34196069-2C983DF5-9436-4BE4-ABAC-AF61E2FF07C7Q36969968-4943BA42-4885-4CA6-B77E-EACDC9E92E82Q40885754-EAFCB32C-5B3E-4CD5-A322-7EFBC031EBD9Q41025628-1521611E-79E0-4040-8AB1-CE7BDDAC93E9Q44190928-4E7A051C-1A00-4CC5-9F26-7619A15CF7FEQ45733521-C6FAE4C8-65BE-454F-BF63-1CE1B584439AQ47245565-DB238A28-5476-4D29-993E-27D7C1593344Q47375729-AD4541DD-AD3F-4850-9BDD-872F4A85FF06Q50509323-D2BD2C12-10C0-4FC4-B442-1238A42167F4Q51800073-F4A407FA-2AC4-4D30-9B21-B725D63F50C5Q54574332-6B40A0A2-23EB-4E80-B48B-49B2EC91ABA3Q54628562-1840C495-3D96-44A0-856B-C051C81085B7Q61268441-2220B2E9-2953-4462-8AB6-EB54C7F391E1Q73420837-B9D73C94-FBD9-4FAB-AE47-E8E75CDCC2AFQ73595188-7A75C3FE-02DA-4AAA-A061-08FE90A5FF1EQ81484604-94ADA49A-3D91-4174-98F5-7B61091C36DDQ94491081-CA6410EF-F1F9-4750-96DE-857C699ACE9F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul Zajac
@ast
Paul Zajac
@en
Paul Zajac
@es
Paul Zajac
@nl
Paul Zajac
@sl
type
label
Paul Zajac
@ast
Paul Zajac
@en
Paul Zajac
@es
Paul Zajac
@nl
Paul Zajac
@sl
prefLabel
Paul Zajac
@ast
Paul Zajac
@en
Paul Zajac
@es
Paul Zajac
@nl
Paul Zajac
@sl
P106
P21
P31
P496
0000-0003-3769-2218